BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab (BGB-A317) to Treat Nasopharyngeal Cancer in China
Shots:
- The sBLA is based on P-III RATIONALE 309 trial evaluating the efficacy & safety of tislelizumab + CT vs PBO + CT in a ratio (1:1) in 263 Asian patients with recurrent or metastatic NPC
- The 1EPs of a trial is PFS as assessed by IRC in ITT population & 2EPs includes OS- ORR- DoR- investigator-assessed PFS- the safety profile was consistent with its known risks with no new safety signals observed with an addition of CT
- Tislelizumab is a humanized IgG4 anti-PD-1 mAb- designed to minimize binding to FcγR on macrophages. In Jan’21- BeiGene & Novartis entered into a license agreement in which Novartis got rights to develop- manufacture & commercialize the therapy in North America- EU & Japan
| Ref: Businesswire | Image: Forbes
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com